Asarina Pharma receives final approval for landmark phase IIa Tourette study
(Stockholm, Sweden, 22 December, 2021.) The Capital Region of Denmark (Region Hovedstaden) has now given official approval to Asarina Pharma to begin its phase IIa study in Tourette, following a four-month delay due to an administrative backlogThe phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette department, and Bispebjerg University hospital. 30 patients ranging from 12 to 45 years old will be included in the study. There is an acute un-met need for a safe and effective pharmaceutical